SACT regimen received in 1L and 2L of therapy, overall and by time period in patients with incident stage IIIB–IV NSCLC at diagnosis
| Overall | 2007–2012 | 2013–2017 | |
| N (%) | n (%) | n (%) | |
| 1L of therapy | 648 | 338 | 310 |
| Platinum-based chemotherapy** | 549 (84.7) | 292 (86.4) | 257 (82.9) |
| Carboplatin based | 456 (70.4) | 258 (76.3) | 198 (63.9) |
| Cisplatin based | 93 (14.3) | 34 (10.1) | 59 (19.0) |
| Pemetrexed containing treatments | 225 (34.7) | 86 (27.0) | 139 (44.8) |
| Non-platinum chemotherapy | 7 (1.1) | 7 (2.1) | 0 |
| TKIs | 63 (9.7) | 21 (6.2) | 42 (13.5) |
| Gefitinib | 29 (4.5) | 15 (4.4) | 14 (4.5) |
| Erlotinib | 15 (2.3) | 3 (0.9) | 12 (3.9) |
| Afatinib | 13 (2.0) | 0 | 13 (4.2) |
| Checkpoint inhibitors (anti-PD-L1) | 7 (1.1) | 0 | 7 (2.3) |
| Pembrolizumab | 7 (1.1) | 0 | 7 (2.3) |
| Clinical trial | 22 (3.4) | <20 | <5 |
| 2L of therapy | 223 | 119 | 104 |
| Platinum-based chemotherapy | 34 (15.2) | 11 (9.2) | 23 (22.1) |
| Non-platinum chemotherapy | 21 (9.4) | 8 (6.7) | 13 (12.5) |
| Docetaxel | 16 (7.2) | 5 (4.2) | 11 (10.6) |
| TKIs | 141 (63.2) | 99 (83.2) | 42 (40.4) |
| Erlotinib | 113 (50.7) | 96 (80.7) | 17 (16.3) |
| Crizotinib | 7 (3.1) | 0 | 7 (6.7) |
| Nintedanib + docetaxel | 10 (4.5) | 0 | 10 (9.6) |
| Checkpoint inhibitors (anti-PD-L1) | 19 (8.5) | 0 | 19 (18.3) |
| Pembrolizumab | 10 (4.5) | 0 | 10 (9.6) |
| Nivolumab | 7 (3.1) | 0 | 7 (6.7) |
| Clinical trial | 6 (2.7) | 0 | 6 (5.8) |
Patient numbers <5 have been masked; data are not shown for treatments with patient numbers <5 for all populations shown.
*Platinum based chemotherapy included any regimen with a platinum agent as monotherapy or in combination, and was further defined as ‘carboplatin based’, ‘cisplatin based’ (including regimens where carboplatin and cisplatin were both used) and ‘pemetrexed included’ (any platinum-based regimen also including pemetrexed).
1L, first-line therapy; 2L, second-line therapy; NSCLC, non-small cell lung cancer; PD-L1, programmed death ligand 1; SACT, systematic anticancer therapy; TKIs, tyrosine kinase inhibitors.